Citadel Advisors
REVBW icon

Citadel Advisors’s Revelation Biosciences Warrant REVBW Stock Holding History

Citadel Advisors’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116 Sell
18,716
-13,684
-42% -$142 ﹤0.01% 13572
2026
Q1 		$285 Buy
32,400
+302
+0.9% +$3 ﹤0.01% 12856
2025
Q4 		$257 Buy
32,098
+300
+0.9% +$3 ﹤0.01% 12505
2025
Q3 		$321 Sell
31,798
-4,250
-12% -$61 ﹤0.01% 12616
2025
Q2 		$433 Sell
36,048
-520
-1% -$6 ﹤0.01% 12290
2025
Q1 		$366 Sell
36,568
-1,667
-4% -$26 ﹤0.01% 14276
2024
Q4 		$268 Buy
38,235
+8,835
+30% +$103 ﹤0.01% 14357
2024
Q3 		$423 Sell
29,400
-16,453
-36% -$230 ﹤0.01% 14020
2024
Q2 		$917 Sell
45,853
-674
-1% -$11 ﹤0.01% 13890
2024
Q1 		$1.23K Buy
46,527
+32,266
+226% +$445 ﹤0.01% 14158
2023
Q4 		$151 Sell
14,261
-2,220
-13% -$28 ﹤0.01% 14113
2023
Q3 		$279 Buy
16,481
+1,761
+12% +$29 ﹤0.01% 14099
2023
Q2 		$294 Sell
14,720
-2,419
-14% -$44 ﹤0.01% 14158
2023
Q1 		$278 Buy
+17,139
New +$430 ﹤0.01% 14532

Other funds holding REVBW

LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SIA
Soltis Investment Advisors St. George, Utah $1.8B AUM 27.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's REVBW Position: Q2 2026 in Review

Citadel Advisors reduced its Revelation Biosciences Warrant (REVBW) stake by 42% in Q2 2026, selling an estimated $142 and leaving 18,716 shares worth $116. The position accounts for ﹤0.01% of the portfolio, ranked #13572.

Citadel Advisors first reported a position in REVBW in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.23K in Q1 2024. 13 funds tracked by Wall St. Rank hold REVBW as of Q2 2026.

  • Citadel Advisors held 18,716 shares of Revelation Biosciences Warrant worth $116 as of Q2 2026.
  • Citadel Advisors sold 13,684 Revelation Biosciences Warrant shares in Q2 2026, an estimated $142.
  • Revelation Biosciences Warrant made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13572 holding.
  • Citadel Advisors first reported a position in Revelation Biosciences Warrant in Q1 2023 and has held it in 14 quarters since.
  • Citadel Advisors's Revelation Biosciences Warrant position peaked at $1.23K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.